Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Related Keywords

Ukraine ,Chicago ,Illinois ,United States ,Russia ,Daniel Vitt ,Edna Kaplan ,Hella Kohlhof ,Franziska Buri ,Paula Schwartz ,Jessica Breu ,Nasdaq ,Prnewswire Immunic Inc ,Rx Communications Group ,Exchange Commission ,Immunic Inc ,Orally Available ,Systemically Acting ,Highly Selective ,Potent Small Molecule Modulator ,Targets Regeneration ,Bowel Epithelium ,Intestinal Barrier Function ,Recently Released Phase ,Data Showing Beneficial Effects ,Celiac Disease Histology ,Disease Symptoms ,Nutrient Absorption ,Presented Today ,Digestive Disease Week ,Chief Scientific Officer ,Chief Executive Officer ,Senior Medical Director ,First In Human Trial ,Poster Number ,Gluten Related ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Immunic ,Nc ,